Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 4/20 | 0.62 |
| ▸ | ABL1 | P00519 | 4/20 | 0.61 |
| ▸ | BCR | P11274 | 4/20 | 0.61 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 3/20 | 0.49 |
| ▸ | SRC | P12931 | 3/20 | 0.49 |
| ▸ | PRKACA | P17612 | 2/20 | 0.49 |
| ▸ | PRKACG | P22612 | 2/20 | 0.49 |
| ▸ | PRKACB | P22694 | 2/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.49 |
| ▸ | CDK1 | P06493 | 3/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.45 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.45 |
| ▸ | CDK4 | P11802 | 2/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.45 |
| ▸ | CCND1 | P24385 | 2/20 | 0.45 |
| ▸ | CDK2 | P24941 | 2/20 | 0.45 |
| ▸ | CCND3 | P30281 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2323589 | 0.91 | CTSC (0.53) | PRKCAABL1BCREGFRCDK1 | |
| SCHEMBL2323561 | 0.91 | IGF1R (0.56) | PRKCAABL1BCRCSNK2A1EGFR | |
| SCHEMBL2330310 | 0.89 | CDK1 (0.47) | PRKCAABL1BCRCSNK2A1EGFR | |
| SCHEMBL2330503 | 0.88 | IGF1R (0.53) | PRKCAABL1BCRCSNK2A1EGFR | |
| SCHEMBL8837807 | 0.86 | PRKCA (0.79) | PRKCAABL1BCRCSNK2A1EGFR | |
| SCHEMBL2327107 | 0.83 | FGFR2 (0.56) | EGFRCDK1FGFR2FGFR3CCNB2 | |
| SCHEMBL2325853 | 0.81 | CDK1 (0.50) | EGFRCDK1FGFR2FGFR3CCNB2 | |
| SCHEMBL2323714 | 0.81 | CDK1 (0.49) | PRKCAABL1BCRPRKCDCDK1 | |
| SCHEMBL2329332 | 0.81 | KDM4E (0.58) | CDK1CCNB2CDK4CCNB1CCNA2 | |
| SCHEMBL2323869 | 0.80 | CDK2 (0.52) | SRCPRKACACDK1CCNB2CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110218188-A1 | SUBSTITUTED (PYRIDYL)-AZINYLAMINE DERIVATIVES AS FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2011-09-08 | — | — | US | claimed |
| EP-2356107-A1 | SUBSTITUTED (PYRIDYL)-AZINYLAMINE DERIVATIVES AS FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2011-08-17 | — | — | EP | claimed |
| WO-2010055077-A1 | SUBSTITUTED (PYRIDYL)-AZINYLAMINE DERIVATIVES AS FUNGICIDES | BAYER CROPSCIENCE SA (FR) | 2010-05-20 | — | — | WO | claimed |
| US-20110218188-A1 | SUBSTITUTED (PYRIDYL)-AZINYLAMINE DERIVATIVES AS FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2011-09-08 | — | — | US | disclosed |
| EP-2356107-A1 | SUBSTITUTED (PYRIDYL)-AZINYLAMINE DERIVATIVES AS FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010055077-A1 | SUBSTITUTED (PYRIDYL)-AZINYLAMINE DERIVATIVES AS FUNGICIDES | BAYER CROPSCIENCE SA (FR) | 2010-05-20 | — | — | WO | disclosed |
| EP-1218360-B1 | TRIAZINE KINASE INHIBITORS | AMGEN INC (US) | 2008-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218188-A1 | SUBSTITUTED (PYRIDYL)-AZINYLAMINE DERIVATIVES AS FUNGICIDES | CYP1A1, CYP1A2, PNPO | PRKCA 4641/4885ABL1 235/4885BCR 2501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.